Natasha N Pettit1, Marisa H Miceli2, Christina G Rivera3, Prasanna P Narayanan3, Anthony J Perissinotti4, Meier Hsu5, Jennifer Delacruz6, Zivile Gedrimaite7, Zhe Han1, Jennifer Steinbeck6, Jennifer Pisano6, Susan K Seo7, Alla Paskovaty8. 1. Department of Pharmacy, The University of Chicago Medicine, Chicago, IL, USA. 2. Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, MI, USA. 3. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. 4. Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, USA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Medicine, Section of Infectious Diseases and Global Health, The University of Chicago Medicine, Chicago, IL, USA. 7. Department of Medicine, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
Objectives: The association of posaconazole serum concentrations and toxicity is unclear. An assessment of whether levels obtained with the delayed-release tablet (DRT) formulation are correlated with abnormal liver function test (LFT) results and/or QTc prolongation was undertaken. Methods: This was a multicentre, retrospective, observational study of adult patients with cancer between 26 November 2013 and 14 November 2014. Patients were included if they received posaconazole DRT with a posaconazole level obtained between days 5 and 14. Clinical data, including demographics, hepatotoxic medications, posaconazole levels, LFTs and QTc intervals, were obtained. Association of factors with changes in LFTs and QTc prolongation was assessed using linear and logistic regression. Results: One hundred and sixty-six study patients were included. The median posaconazole level was 1250 (range 110-4220) ng/mL and the median time until level was 6 (range 5-14) days. There was a statistically significant increase in AST ( P < 0.001), ALT ( P < 0.001), alkaline phosphatase (ALK) ( P < 0.001), total bilirubin (TBILI) ( P < 0.001) and QTc ( P = 0.05) from baseline. Posaconazole levels were not associated with increases in AST [β (SE) = -0.33 (2.2), P = 0.88], log ALT [β (SE) = -0.02 (0.03), P = 0.63], ALK [β (SE) = 2.2 (2.9), P = 0.46] and TBILI [β (SE) = -0.01 (0.04), P = 0.88]. For each additional hepatotoxic medication, there was a mean change in TBILI of 0.13 mg/dL ( P = 0.02) and ALK of 7.1 U/L ( P = 0.09). No statistically significant association between posaconazole level and QTc interval prolongation was found. Conclusions: We did not identify an association between posaconazole serum concentrations and LFT elevations or QTc prolongation. However, some LFTs were found to increase with more hepatotoxic medications administered.
Objectives: The association of posaconazole serum concentrations and toxicity is unclear. An assessment of whether levels obtained with the delayed-release tablet (DRT) formulation are correlated with abnormal liver function test (LFT) results and/or QTc prolongation was undertaken. Methods: This was a multicentre, retrospective, observational study of adult patients with cancer between 26 November 2013 and 14 November 2014. Patients were included if they received posaconazole DRT with a posaconazole level obtained between days 5 and 14. Clinical data, including demographics, hepatotoxic medications, posaconazole levels, LFTs and QTc intervals, were obtained. Association of factors with changes in LFTs and QTc prolongation was assessed using linear and logistic regression. Results: One hundred and sixty-six study patients were included. The median posaconazole level was 1250 (range 110-4220) ng/mL and the median time until level was 6 (range 5-14) days. There was a statistically significant increase in AST ( P < 0.001), ALT ( P < 0.001), alkaline phosphatase (ALK) ( P < 0.001), total bilirubin (TBILI) ( P < 0.001) and QTc ( P = 0.05) from baseline. Posaconazole levels were not associated with increases in AST [β (SE) = -0.33 (2.2), P = 0.88], log ALT [β (SE) = -0.02 (0.03), P = 0.63], ALK [β (SE) = 2.2 (2.9), P = 0.46] and TBILI [β (SE) = -0.01 (0.04), P = 0.88]. For each additional hepatotoxic medication, there was a mean change in TBILI of 0.13 mg/dL ( P = 0.02) and ALK of 7.1 U/L ( P = 0.09). No statistically significant association between posaconazole level and QTc interval prolongation was found. Conclusions: We did not identify an association between posaconazole serum concentrations and LFT elevations or QTc prolongation. However, some LFTs were found to increase with more hepatotoxic medications administered.
Authors: M M Chau; D C M Kong; S J van Hal; K Urbancic; J A Trubiano; M Cassumbhoy; J Wilkes; C M Cooper; J A Roberts; D J E Marriott; L J Worth Journal: Intern Med J Date: 2014-12 Impact factor: 2.048
Authors: Ioannis Kyriakidis; Athanasios Tragiannidis; Silke Munchen; Andreas H Groll Journal: Expert Opin Drug Saf Date: 2016-12-16 Impact factor: 4.250
Authors: Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect Journal: Clin Infect Dis Date: 2006-11-28 Impact factor: 9.079
Authors: Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: Walter K Kraft; Peter S Chang; Marlou L P S van Iersel; Hetty Waskin; Gopal Krishna; Wendy M Kersemaekers Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: Aileen E Boyd; Simon Modi; Susan J Howard; Caroline B Moore; Brian G Keevil; David W Denning Journal: Clin Infect Dis Date: 2004-09-23 Impact factor: 9.079
Authors: Russell E Lewis; Dimitrios P Kontoyiannis; Pierluigi Viale; Eric M Sarpong Journal: Antimicrob Agents Chemother Date: 2019-09-16 Impact factor: 5.191
Authors: Adam J DiPippo; Patrick M McDaneld; Frank P Tverdek; Dimitrios P Kontoyiannis Journal: Antimicrob Agents Chemother Date: 2021-09-27 Impact factor: 5.191
Authors: Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann Journal: Drugs Date: 2020-05 Impact factor: 9.546
Authors: Lisa F Shubitz; Sallianne Schlacks; Polina Vishkautsan; Christine D Butkiewicz; Kate A Worthing Journal: J Vet Intern Med Date: 2021-10-18 Impact factor: 3.333